Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma with a Buy rating and $4 price target. The company's lead asset CUE-401 is a novel bispecific for autoimmune disease, the analyst tells investors in a research note. The firm believes preclinical data show "strong mechanistic validation and broad efficacy" across autoimmune models.
